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     A case of retroperitoneal malignant fibrous histiocytoma （MFH） treated with combina－
  tion chemotherapy regimen of cyclophosphamide， vincristine， adriamycifl and dimethyl triazeno
  imidazole carboxamide （CYVADIC） is reported．
     The patient was a 37－year－old man who was admitted to our University Hospital with
  complaints of cough， dyspnea and right lower leg pain． His past history included retroperi－
  toneal MFH diagnosed by biopsy specimens， and right nephrectomy with colostomy for right
  ureteral obstruction about 6 months earlier．
     Roentgenographic examination revealed liver， bone and multiple pulmonary metastases．
     CYVADIC combination chemotherapy was started on June， 22， 1981． Administration
  schedule was as follows； cyclophosphamide （CPM） 400 mg on day 2， vincristine （VCR） 1 mg
  ／day on days 1 aRd 5， adriamycin （ADM） 40 mg on day 2， dimethyl triazeno imidazole carboxa－
  mide （DTIC） 200 mg／day on days 1 to 5． This regimen was repeated at 4 weeks intervals．
     Partial remission was achieved after three cycles of this treatment． As maintenance
  therapy， the regimen was changed to CPM plus DTIC every 5 or 6 weeks． The disease was
  arrested for about 6 months， but progression of the tumor was noticed on March， 1982．
     CYVADIC treatment was repeated again， but the relapsed tumor did not show any
  response． And the patient died 15 months after the start of chemotherapy．
     Considering the difficulty of medical treatment for MFH， the case herein reported
  sugg’ests that this CYVADIC therapy may be an effective modality for this disease．












































血液化学；T．P．7．99／dl， AIG 1．o， GoT 25 u／L，
GPT 17UIL， r－GTP 94 U／L， ALP 289 U／L，
LDH 280 UIL， Na 139 mEq／L， K 4．2 mEq／L，
Cl leO mEq／L， Ca 4．7 mEq／L， lnorg． P 4．4 mg／dl，
Creatinine 1．2 mg／dl， BUN 12 mg／dl， U．A． 5．3
mg／dl， CRP 3＋・動脈血ガス所見；pH 7．454，


































始した．すなわちDTIc 200 mg／day（125 mg／m2／
day）を5日間連続投与し，第1日目と第5日目に
vcR l mg／day （o．63 mg／m2／day），第2日目に



















Fig 1． Chest X－ray films






















show 30 per cent reduction of multiple pulmonary
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Fig． 2． CT scan reveals the 1iver metastatic lesion
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腸間膜動脈にDTIC 200 mg， ADM 20 mg，また，





































Microphotogram of the gluteal tumor initially
diagnosed as leiomyosarcoma （H ＆ E， ×100）
難
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 Fig． 5． Microphotogram of the retroperitoneal MFH
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。 CY （cpM） ： Cyclophosphamide
o VCR ： Vincristine
oADM ：Adriamy¢in
o DTIC ： Dimetyl triazeno imidazole carboxamide
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／m2 day 1，VCR 1．5 mg／m2／day days 1 and 5，
ADM 50 mg／m2 day 1， DTIC 250皿g／m2／day
days l to 5で，1法はcPM 500 mg／m2 day 2，
VCR 1．5 mg／m2／day days 1 and weekly x 7，
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